Showing results (451-460 of 563) with videos related to
Sort By:
Pageof 57
European Urology Oncology|February 8, 2023
The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence After Previous External Radiation Therapy: Phase 1 Results from the GETUG-AFU 31 StudyDavid Pasquier, Thomas Lacornerie, Stéphane Supiot, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 17, 2021
Safety of PSMA-Targeted Molecular Radioligand Therapy with <sup>177</sup>Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)Jeremie Calais, Johannes Czernin, Pan Thin, et al.The Lancet. Oncology|January 21, 2014
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised studyJean-François Bosset, Gilles Calais, Laurent Mineur, et al.Sarcoma|June 19, 2023
Fibroblast Activation Protein Expression in SarcomasJacquelyn N Crane, Danielle S Graham, Christine E Mona, et al.European Urology|March 19, 2023
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)Robert Seifert, Louise Emmett, Steven P Rowe, et al.Cancer|October 18, 2025
Prostate-specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long-term survivalKemal Caglar Gogebakan, Zizi Elsisi, Felipe Montano-Campos, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 28, 2025
Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule of <sup>177</sup>Lu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT): Study ProtocolAdrien Holzgreve, Astrid Delker, Zachary Ells, et al.International Journal of Endocrinology|December 24, 2011
Clinical and Laboratorial Features That May Differentiate 46,XY DSD due to Partial Androgen Insensitivity and 5α-Reductase Type 2 DeficiencyNélio Neves Veiga-Junior, Pedro Augusto Rodrigues Medaets, Reginaldo José Petroli, et al.Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|August 6, 2005
[Propositions for the selection and the delineation of peritumoral microscopic disease volumes in oral cavity and oropharyngeal cancers (lymph nodes excluded)]M Lapeyre, P Henrot, M Alfonsi, et al.European Journal of Nuclear Medicine and Molecular Imaging|June 17, 2021
Head-to-head intra-individual comparison of biodistribution and tumor uptake of <sup>68</sup>Ga-FAPI and <sup>18</sup>F-FDG PET/CT in cancer patientsFrederik L Giesel, Clemens Kratochwil, Joel Schlittenhardt, et al.Pageof 57